Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire LlcfiledCriticalShire Llc
Priority to MYPI20051447priorityCriticalpatent/MY139403A/en
Publication of MY139403ApublicationCriticalpatent/MY139403A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
A PHARMACEUTICAL COMPOSITION COMPRISES A ONCE-A-DAY SUSTAINED RELEASE FORMULATION OF AT LEAST ONE AMPHETAMINE SALT WHICH PROVIDES MEAN PLASMA CONCENTRATION PROFILE ASPECTS IN HUMAN ADHD PATIENTS WHICH ARE SUBSTANTIALLY THE SAME AS THAT PROVIDED BY ADDERALL XR® TYPE PULSATILE FORMULATIONS.
MYPI200514472005-03-312005-03-31Sustained released delivery of amphetamine salts
MY139403A
(en)
Composition comprising baclofen, or a salt, or derivative, or sustained release formulation thereof, for use in the treatment of alzheimer's disease
Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis.
Pharmaceutical composition comprising a methotrexate (mtx) active agent and a 2,2-anhydropyrimidine adjuvant for reducing mtx toxicity and use thereof in the preparation of medicaments